Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT04388943

Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)

Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study) — Recruiting • Cardiology / Cardiovascular • NCT04388943.

📅 12 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT04388943
Sponsor
University Hospitals, Leicester
Start
2010-06-17
ClinicaliQ Trial Snapshot
  • Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study) — Recruiting • Cardiology / Cardiovascular • NCT04388943.
  • What is being tested: The BRICCS Study examines diagnostic and prognostic factors in patients with established cardiovascular disease (coronary artery disease, heart failure, myocardial infarction) compared to community controls, using hospital inpatients and outpatients.
  • Patient eligibility overview: The study enrolls both hospital-based cardiovascular patients across inpatient and outpatient settings alongside community-based control participants without significant cardiovascular disease for comparative analysis.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This project will examine the diagnosis and prognosis of patients with cardiovascular disease in hospital in- and outpatients and compare their characteristics with normal controls from the community. The cardiovascular diseases studied include coronary artery disease, heart failure, heart attacks, valve disease, cardiac surgery, dysrhythmias, aneurysms, embolism, strokes, peripheral vascular disease and hypertension. Current methods for diagnosis and predicting outcome in patients are limited and may lack accuracy. This study will collect clinical details, and blood and urine samples from patients for analysis of proteins, chemicals and genetic biomarkers which…

Eligibility Snapshot
  • : * All outpatients and inpatients with cardiovascular disease, of either gender * Aged 18-90 years old * Examples of conditions include: coronary artery disease, heart failure, heart attacks (myocardial infarction), valve disease, cardiac surgery, dysrhythmias (including atrial fibrillation), aneurysms, embolism, strokes, peripheral vascular disease, hypertension (and its complications, such as left ventricular hypertrophy) or those presenting with chest pain * Healthy volunteers * Aged 18-90 years old * From the community without cardiovascular or other diseases

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Cardiology / Cardiovascular · 30 Mar 2026
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies…
View guideline →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Stroke and TIA: Diagnosis and Initial Management (NICE NG128)
Cardiology / Cardiovascular · 27 Mar 2026
Use FAST recognition (Face, Arms, Speech, Time) in primary care to identify suspected stroke and arrange immediate hospital admission as a medical…
View guideline →